Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $622,608.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 9,520 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $65.40, for a total value of $622,608.00. Following the completion of the sale, the chief operating officer now directly owns 809,852 shares in the company, valued at $52,964,320.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $65.48 on Friday. The stock’s 50 day moving average price is $64.95 and its 200 day moving average price is $58.63. The firm has a market capitalization of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. ANI Pharmaceuticals, Inc. has a one year low of $36.99 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC boosted its stake in shares of ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after buying an additional 15,790 shares during the last quarter. BTC Capital Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $580,000. Los Angeles Capital Management LLC raised its position in shares of ANI Pharmaceuticals by 27.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 24,974 shares of the specialty pharmaceutical company’s stock valued at $1,726,000 after acquiring an additional 5,408 shares in the last quarter. Vanguard Group Inc. increased its position in ANI Pharmaceuticals by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock worth $71,074,000 after buying an additional 156,594 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in ANI Pharmaceuticals in the fourth quarter worth $514,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright lifted their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Guggenheim lifted their price objective on ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Truist Financial lifted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Capital One Financial assumed coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Buy” and an average price target of $80.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.